Case report: Clinical utility and limitations of high-frequency ultrasound for monitoring sonidegib response in nodular basal cell carcinoma: a three-case series.
- 1Department of Ultrasound, Hangzhou Third People's Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
- 2Department of Dermatology, Hangzhou Third People's Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
Abstract
Background
Sonidegib, a Hedgehog pathway inhibitor, can induce clinical and imaging remission in locally advanced basal cell carcinoma (BCC). Residual deep tumor may persist after malignant dermoscopic and ultrasound features disappear. This case series assessed the utility and limitations of 20-30 MHz high-frequency ultrasound (HFUS) for confirming complete imaging remission after sonidegib.Cases presentation
Three patients with nodular BCC received sonidegib 200 mg daily (October 2024-May 2026). Two achieved complete imaging remission, defined as resolution of malignant imaging features with residual non-malignant hypoechoic areas allowed, and underwent surgical resection with histopathological correlation; the third declined surgery. Baseline ultrasound was unavailable, so findings were compared with the earliest 3-4-month follow-up.Results
Response involved lesion shrinkage and loss of intratumoral blood flow. Serial imaging showed gradual resolution of hypoechoic nodules with vascularity on HFUS and blue-gray nests with arborizing vessels on dermoscopy, leaving avascular scar-like structures. Preoperative HFUS residual hypoechoic areas were correlated with histopathology, which showed chronic inflammatory infiltration (case 1) and mild dermal fibrosis (case 2), with no residual tumor. The third patient's malignant features regressed after six months.Conclusions
In this small case series, HFUS monitored deeper tissue changes after targeted therapy. In two histopathologically confirmed patients, complete imaging remission on HFUS plus dermoscopy corresponded to pathological complete response; however, given the small sample and histopathological confirmation in only two patients, this is a possible correspondence rather than evidence of true predictive capability. Post-treatment hypoechoic areas may reflect inflammation, fibrosis, or residual tumor, limiting specificity. Imaging-based complete response should be confirmed by biopsy or excision when feasible. Surgery remains the gold standard; non-surgical patients require close follow-up.
Related
- Dermoscopy guided high-frequency ultrasound features of basal cell carcinoma subtypes compared with histopathology: a multicenter study
- Circulating Biomarkers with Artificial Intelligence for Clinical Risk Assessment and Therapeutic Monitoring: Evidence, Limitations, and Translation
- Fundamental limitations of kilohertz-frequency carriers in afferent fibre recruitment with transcutaneous spinal cord stimulation
- High-frequency ultrasound-derived imaging biomarkers in inflammatory skin diseases
- High-frequency ultrasound point-of-care device to quantify myopia-induced microstructural changes in the anterior sclera
BibTeX
@article{he2026case,
title = {{Case report: Clinical utility and limitations of high-frequency ultrasound for monitoring sonidegib response in nodular basal cell carcinoma: a three-case series.}},
author = {Dandan He and Hailiang Tao and Ke Bian and Junzhu Xu and Tao Wang},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1945673},
url = {https://europepmc.org/article/MED/42908532},
note = {CC BY},
}
RIS
TY - JOUR
TI - Case report: Clinical utility and limitations of high-frequency ultrasound for monitoring sonidegib response in nodular basal cell carcinoma: a three-case series.
AU - Dandan He
AU - Hailiang Tao
AU - Ke Bian
AU - Junzhu Xu
AU - Tao Wang
PY - 2026
DA - 2026/10/07
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1945673
UR - https://europepmc.org/article/MED/42908532
AB - Background Sonidegib, a Hedgehog pathway inhibitor, can induce clinical and imaging remission in locally advanced basal cell carcinoma (BCC). Residual deep tumor may persist after malignant dermoscopic and ultrasound features disappear. This case series assessed the utility and limitations of 20-30 MHz high-frequency ultrasound (HFUS) for confirming complete imaging remission after sonidegib.Cases presentation Three patients with nodular BCC received sonidegib 200 mg daily (October 2024-May 2026). Two achieved complete imaging remission, defined as resolution of malignant imaging features with residual non-malignant hypoechoic areas allowed, and underwent surgical resection with histopathological correlation; the third declined surgery. Baseline ultrasound was unavailable, so findings were compared with the earliest 3-4-month follow-up.Results Response involved lesion shrinkage and loss of intratumoral blood flow. Serial imaging showed gradual resolution of hypoechoic nodules with vascularity on HFUS and blue-gray nests with arborizing vessels on dermoscopy, leaving avascular scar-like structures. Preoperative HFUS residual hypoechoic areas were correlated with histopathology, which showed chronic inflammatory infiltration (case 1) and mild dermal fibrosis (case 2), with no residual tumor. The third patient's malignant features regressed after six months.Conclusions In this small case series, HFUS monitored deeper tissue changes after targeted therapy. In two histopathologically confirmed patients, complete imaging remission on HFUS plus dermoscopy corresponded to pathological complete response; however, given the small sample and histopathological confirmation in only two patients, this is a possible correspondence rather than evidence of true predictive capability. Post-treatment hypoechoic areas may reflect inflammation, fibrosis, or residual tumor, limiting specificity. Imaging-based complete response should be confirmed by biopsy or excision when feasible. Surgery remains the gold standard; non-surgical patients require close follow-up.
SN - 2234-943X
ER -